KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 studyBijal Shah, Roch Houot, Armin Ghobadi et al.|The Lancet|2021Cited by 795
Investigating the Influence of Covariates on Axicabtagene Ciloleucel (axi-cel) Kinetics in Patients with Non-Hodgkin’s LymphomaMagali Chartier, Rhine R. Shen, Saran Vardhanabhuti et al.|Clinical Pharmacokinetics|2024Cited by 5
Abstract CT166: Pretreatment (PreTx) immune cell phenotypes in peripheral blood associated with the tumor immune contexture, product attributes, and durable clinical efficacy in patients with large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel)Justin A. Budka, Adrian Bot, Justin Chou et al.|Cancer Research|2021Cited by 2
Pre and Post-Treatment CD27+ T Cells Track with Clinical Efficacy of Axi-Cel in DLBCL PatientsJustin Chou, Jerome Ritz, Yohei Arihara et al.|Transplantation and Cellular Therapy|2022Cited by 0